JPWO2019193144A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019193144A5
JPWO2019193144A5 JP2020554254A JP2020554254A JPWO2019193144A5 JP WO2019193144 A5 JPWO2019193144 A5 JP WO2019193144A5 JP 2020554254 A JP2020554254 A JP 2020554254A JP 2020554254 A JP2020554254 A JP 2020554254A JP WO2019193144 A5 JPWO2019193144 A5 JP WO2019193144A5
Authority
JP
Japan
Prior art keywords
strand
nucleotides
nucleic acid
conjugate
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020554254A
Other languages
English (en)
Japanese (ja)
Other versions
JP7419252B2 (ja
JP2021520207A (ja
JP2021520207A5 (https=
Publication date
Priority claimed from EP17165007.0A external-priority patent/EP3385380A1/en
Priority claimed from PCT/EP2018/058764 external-priority patent/WO2018185240A1/en
Priority claimed from EP18197795.0A external-priority patent/EP3550022A1/en
Priority claimed from PCT/EP2019/058615 external-priority patent/WO2019193144A1/en
Application filed filed Critical
Publication of JP2021520207A publication Critical patent/JP2021520207A/ja
Publication of JP2021520207A5 publication Critical patent/JP2021520207A5/ja
Publication of JPWO2019193144A5 publication Critical patent/JPWO2019193144A5/ja
Priority to JP2024001366A priority Critical patent/JP2024036347A/ja
Publication of JP7419252B2 publication Critical patent/JP7419252B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020554254A 2017-04-05 2019-04-05 アンチセンス鎖の5’末端でビニルホスホネートを有するsiRNA Active JP7419252B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024001366A JP2024036347A (ja) 2017-04-05 2024-01-09 アンチセンス鎖の5’末端でビニルホスホネートを有するsiRNA

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17165007.0A EP3385380A1 (en) 2017-04-05 2017-04-05 Products and compositions
EP17201405 2017-11-13
PCT/EP2018/058764 WO2018185240A1 (en) 2017-04-05 2018-04-05 Products and compositions
EPPCT/EP2018/058764 2018-04-05
EP18197795.0 2018-09-28
EP18197795.0A EP3550022A1 (en) 2018-04-05 2018-09-28 Products and compositions
PCT/EP2019/058615 WO2019193144A1 (en) 2018-04-05 2019-04-05 siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024001366A Division JP2024036347A (ja) 2017-04-05 2024-01-09 アンチセンス鎖の5’末端でビニルホスホネートを有するsiRNA

Publications (4)

Publication Number Publication Date
JP2021520207A JP2021520207A (ja) 2021-08-19
JPWO2019193144A5 true JPWO2019193144A5 (https=) 2023-11-15
JP2021520207A5 JP2021520207A5 (https=) 2023-11-15
JP7419252B2 JP7419252B2 (ja) 2024-01-22

Family

ID=61899310

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020504435A Active JP7247167B2 (ja) 2017-04-05 2018-04-05 産物及び組成物
JP2020554254A Active JP7419252B2 (ja) 2017-04-05 2019-04-05 アンチセンス鎖の5’末端でビニルホスホネートを有するsiRNA
JP2023039774A Active JP7495544B2 (ja) 2017-04-05 2023-03-14 産物及び組成物
JP2024001366A Pending JP2024036347A (ja) 2017-04-05 2024-01-09 アンチセンス鎖の5’末端でビニルホスホネートを有するsiRNA

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020504435A Active JP7247167B2 (ja) 2017-04-05 2018-04-05 産物及び組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023039774A Active JP7495544B2 (ja) 2017-04-05 2023-03-14 産物及び組成物
JP2024001366A Pending JP2024036347A (ja) 2017-04-05 2024-01-09 アンチセンス鎖の5’末端でビニルホスホネートを有するsiRNA

Country Status (18)

Country Link
US (2) US11174483B2 (https=)
EP (2) EP3607068B1 (https=)
JP (4) JP7247167B2 (https=)
KR (1) KR102589803B1 (https=)
CN (2) CN110573619B (https=)
AU (2) AU2018247924B2 (https=)
CA (2) CA3057561C (https=)
DK (1) DK3607068T3 (https=)
ES (1) ES2936109T3 (https=)
FI (1) FI3607068T3 (https=)
HR (1) HRP20221547T1 (https=)
HU (1) HUE061894T2 (https=)
IL (2) IL269576B2 (https=)
LT (1) LT3607068T (https=)
PL (1) PL3607068T3 (https=)
RS (1) RS63887B1 (https=)
SI (1) SI3607068T1 (https=)
WO (1) WO2018185240A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102365961B1 (ko) 2011-03-29 2022-02-23 알닐람 파마슈티칼스 인코포레이티드 Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
EP4029942A1 (en) 2017-04-05 2022-07-20 Silence Therapeutics GmbH Products and compositions
JP7155239B2 (ja) * 2017-04-05 2022-10-18 サイレンス・セラピューティクス・ゲーエムベーハー 産物及び組成物
EP3598995A1 (en) * 2018-07-26 2020-01-29 Silence Therapeutics GmbH Products and compositions
CN111973619B (zh) * 2019-05-23 2024-01-30 苏州瑞博生物技术股份有限公司 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
US20240240187A1 (en) 2021-04-27 2024-07-18 Silence Therapeutics Gmbh Sirna targeting tmprss6 for the treatment of myeloproliferative disorders
TWI868755B (zh) 2022-06-24 2025-01-01 丹麥商諾佛 儂迪克股份有限公司 抑制跨膜絲胺酸蛋白酶6(tmprss6)表現的組成物及方法
WO2024060649A1 (zh) * 2022-09-29 2024-03-28 广州必贝特医药股份有限公司 用于抑制TMPRSS6基因表达的siRNA或其盐、药物及其应用
EP4687983A1 (en) 2023-03-27 2026-02-11 Silence Therapeutics GmbH Compounds and compositions for use in stem cell transplantation
WO2025132845A1 (en) 2023-12-21 2025-06-26 Silence Therapeutics Gmbh Galnac phosphoramidites and their uses
WO2025163186A1 (en) * 2024-02-01 2025-08-07 Silence Therapeutics Gmbh Conjugated nucleic acids and nucleic acids comprising locked nucleosides and inverted nucleotides for inhibiting gene expression in a cell
WO2026003163A1 (en) 2024-06-26 2026-01-02 Silence Therapeutics Gmbh Sirna against tmprss6 for treating polycythemia vera

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
EP2305812A3 (en) * 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
KR101869570B1 (ko) * 2010-04-28 2018-06-20 아이오니스 파마수티컬즈, 인코포레이티드 변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
KR102365961B1 (ko) * 2011-03-29 2022-02-23 알닐람 파마슈티칼스 인코포레이티드 Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
EP3650544A1 (en) * 2011-11-07 2020-05-13 Ionis Pharmaceuticals, Inc. Modulation of tmprss6 expression
KR102486617B1 (ko) 2013-05-22 2023-01-12 알닐람 파마슈티칼스 인코포레이티드 Tmprss6 조성물 및 이의 사용 방법
IL316808A (en) * 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
WO2016055601A1 (en) * 2014-10-10 2016-04-14 F. Hoffmann-La Roche Ag Galnac phosphoramidites, nucleic acid conjugates thereof and their use
WO2016085852A1 (en) * 2014-11-24 2016-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
US20160272970A1 (en) * 2015-03-17 2016-09-22 Arrowhead Madison Inc. RNA Interference Agents
EP3228326A1 (en) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleic acid linked to a trivalent glycoconjugate
JP7155239B2 (ja) * 2017-04-05 2022-10-18 サイレンス・セラピューティクス・ゲーエムベーハー 産物及び組成物
EP4029942A1 (en) * 2017-04-05 2022-07-20 Silence Therapeutics GmbH Products and compositions

Similar Documents

Publication Publication Date Title
JP2019214587A5 (https=)
JP2023068035A5 (https=)
JPWO2019193144A5 (https=)
ES2936863T3 (es) Métodos para tratar infección por hepatitis B
JP2023093644A (ja) アンジオテンシノーゲンの発現を調節するための化合物及び方法
JP2023103244A5 (https=)
JP2009514877A5 (https=)
JP2016520312A5 (https=)
JP2018529732A5 (https=)
JP2022503850A5 (https=)
IL316808A (en) Modified double-stranded RNA materials and their uses
JP2021507709A5 (https=)
JP2020529197A5 (https=)
JPWO2019183164A5 (https=)
JPWO2022032288A5 (https=)
JP2015513398A5 (https=)
CN115698288A (zh) 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
JPWO2020206350A5 (https=)
JP2019196384A5 (https=)
CN115702006A (zh) 缀合基团及其缀合物
JP2022530678A (ja) 短縮センス鎖を有する二本鎖核酸阻害剤分子
CA3200094A1 (en) Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
CA2929818A1 (en) Modified dna quadruplex-forming oligonucleotides and methods of use
JP2021517909A5 (https=)
MX2024013992A (es) Composiciones y metodos para inhibir la expresion de snca